Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
Geburtshilfe Frauenheilkd 2012; 72(10): R47-R62
DOI: 10.1055/s-0032-1327778
DOI: 10.1055/s-0032-1327778
GebFra-Weiterbildung | Refresher
Onkologische Therapien und Haarverlust
Further Information
Publication History
Publication Date:
31 October 2012 (online)
Zusammenfassung
Für den therapiebedingten Haarverlust existieren bisher keine effektiven Präventions- und Therapiemöglichkeiten. Gerade beim Haarverlust unter Chemotherapie, der sicherlich den schwerwiegendsten unter allen Therapien darstellt, sind zwar verschiedene Ansätze vorhanden, jedoch gibt es bisher noch keine Erfolg versprechende Maßnahme. Den ältesten und erprobtesten Ansatz stellt das Scalp-Cooling dar, welcher aber einen enormen technischen Aufwand sowie einige Risiken birgt.
Medikamentöse Therapien stehen nur in sehr limitiertem Maße zur Verfügung und zeigen bisher keinen durchschlagenden Erfolg. Am häufigsten werden Minoxidil und östrogenhaltige Lösungen angewendet, die jedoch die Alopezie nicht verhindern, sondern nur verkürzen können. Hormonhaltige Therapien sind allerdings bei hormonrezeptorpositiven Karzinomen kritisch zu sehen.
Die wichtigsten Punkte bei fehlenden Therapiemöglichkeiten zum Schutz vor Haarverlust sind die Aufklärung der Patientin und die Vermittlung von Bewältigungsstrategien.
-
Literatur
- 1 McGarvey EL, Leon-Verdin M, Baum L et al. An evavluation of a computer imaging program to prepare women for chemotherapy-related alopecia. Psycho-Oncology 2010; 19: 756-766
- 2 Mols F, van den Hurk CJ, Vingerhoets JJM et al. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 2009; 17: 181-189
- 3 Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology 2008; 17: 317-328
- 4 Batchelor D. Hair and cancer chemotherapy: consequences and nursing care – a literature study. Eur J Cancer Care (Engl ) 2001; 10: 147-163
- 5 McElwee KJ, Shapiro J. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett 2012; 17: 1-4
- 6 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001; 9: 283-289
- 7 Roe H. Chemotherapy-induced alopecia: advice and support for hair loss. Br J Nurs 2011; 20: 4-11
- 8 Trueb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care 2010; 4: 281-284
- 9 Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006; 23: 2505-2514
- 10 Chon SY, Champion RW, Geddes ER et al. Chemotherapy-induced alopecia. J Am Acad Dermatol 2011; 67: e37-e47
- 11 Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett 2010; 15: 5-7
- 12 Alonso E, Fuchs E. The hair cycle. J Cell Sci 2006; 119: 391-393
- 13 Ohnemus U, Uenalan M, Inzunza J et al. The hair follicle as an estrogen target and source. Endocr Rev 2006; 27: 677-706
- 14 Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001; 81: 449-494
- 15 Röcken M et al. Taschenatlas Dermatologie. Stuttgart: Thieme Verlag; 2010: 11
- 16 Sterry W et al. Kurzlehrbuch Dermatologie. Stuttgart: Thieme Verlag; 2011: 243
- 17 Otomo S. Hair growth effect of minoxidil. Nihon Yakurigaku Zasshi 2002; 119: 167-174
- 18 Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003; 8: 72-75
- 19 Paus R. Principles of hair cycle control. J Dermatol 1998; 25: 793-802
- 20 Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther 2011; 24: 432-442
- 21 Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2009; 10: 333-336
- 22 Van den Hurk CJ, Mols F, Vingerhoets JJM et al. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-Oncology 2010; 19: 701-709
- 23 Imanishi H, Tsuruta D, Tateishi C et al. Laminin-511, inducer of hair-growth, is down-regulated and its suppressor in hair growth, laminin-322 up-regulated in chemotherapy-induced alopecia. J Dermatol Sci 2010; 58: 43-54
- 24 Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004; 12: 543-549
- 25 Im Internet: http://www.fachinfo.de Stand: 17.5.2012
- 26 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012 Im Internet: http://www.krebsgesellschaft.de/download/S3_Brustkrebs_Update_2012_OL_Langversion.pdf Stand: 17.5.2012
- 27 Gateley CA, Bundred NJ. Alopecia and breast disease. BMJ 1997; 314 (7079) 481
- 28 Jamin C. Androgenetic alopecia. Ann Dermatol Venereol 2002; 129 (5 Pt 2) 801-803
- 29 Li W, Li C, Lu Z. Vascular endothelial growth factor and its receptors my be one mechanism for androgenetic alopecia. Med Hypotheses 2009; 72: 366-367
- 30 Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-417
- 31 Conrad F, Paus R. Estrogens and the hair follicle. JDDG 2004; 2: 412-423
- 32 Ehmann LM, Heinemann V, Wollenberg A. Neue Tyrosinkinase- und EFGR-Inhibitoren in der Tumortherapie. Herz und Haut als wichtige Schädigungsorgane. Teil B: Haut. Internist 2011; 52: 1359-1364
- 33 Boehm S, Rothermundt C, Hess D et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly – a mini review. Gerontology 2010; 56: 303-309
- 34 Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749
- 35 Baselga J, Cortés J, Kim SB et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
- 36 Mokbel K, Hassanally D. From HER2 to herceptin. Curr Med Res Opin 2001; 17: 51-59
- 37 Zander T, Hallek M. Thyrosinkinaseinhibitoren in der Onkologie. Internist 2011; 52: 595-600
- 38 Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010; 5: 295-296
- 39 Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336
- 40 Franklin MC, Kendall DC, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328
- 41 Im Internet: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm307592.htm Stand: 17.5.2012
- 42 Im Internet: http://www.ema.europa.eu Stand: 17.5.2012
- 43 Affara NI, Trempus CS, Schanbacher BL et al. Activation of Akt and mTOR in CD34+/K15+keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res 2006; 26: 2805-2820
- 44 Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012; 118: 3014-3025
- 45 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
- 46 Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. BJD 2009; 161: 1045-1051
- 47 Anderson JE, Hunt JM, Smith IE. Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. Br Med J (Clin Res Fd) 1981; 282: 423-424
- 48 Grevelman EG, Breed WPM. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005; 16: 352-358
- 49 Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J 1993; 86: 489-496
- 50 Poder TG, He J, Lemieux R. Effectiveness of scalp cooling in chemotherapy. Bull Cancer 2011; 98: 1119-1129
- 51 Van den Hurk CJ, Peerbooms M, Van de Poll-Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51: 497-504
- 52 Auvinen PK, Mähönen UA, Soininen KM et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 2010; 96: 271-275
- 53 Lemieux J, Amireault C, Provencher L et al. Incidence of scalp metastase in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 2009; 118: 547-552
- 54 Van de Sande MA, van den Hurk CJ, Breed WP et al. Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd 2010; 154: A21-A34
- 55 Lachgar S, Charveron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-411
- 56 Rossi A, Cantisani C, Melis L et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov 2012; 6: 130-136
- 57 Chen G, Baechle A, Nevins TD et al. Protection against cyclophosphamid-induced alopecia and inhibition of mammary tumor growth by topical 1,25-Dihyroxyvitamin D3 in mice. Int J Cancer 1998; 75: 303-309
- 58 Peters EMJ, Foitzik K, Paus R et al. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001; 117: 173-178
- 59 Katikaneni R, Ponnapakkam T, Suda H et al. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer 2011; 131: E813-E821
- 60 Münstedt K, Manthey N, Sachsse S et al. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997; 5: 139-143
- 61 World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. Im Internet: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf Stand 17.5.2012
- 62 NCI-CTAE Version 4.0. Im Internet: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14.xls Stand 21.9.2012